TrialBlood neoplasia2024

Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma.

Amrita Y Krishnan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.